Sympathovagal Balance in Smoking Cessation

PHASE4CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

April 30, 2013

Conditions
Smoking Cessation
Interventions
DRUG

Varenicline

0.5-2 mg per day, oral use

DRUG

Placebo

1-2 tablets per day, oral use

DRUG

Nicorette TX

10-15 mg per day, transdermal use (patches)

Trial Locations (1)

37075

University Medical Center, Göttingen

All Listed Sponsors
collaborator

University Medical Center Goettingen

OTHER

lead

Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH

OTHER

NCT01474265 - Sympathovagal Balance in Smoking Cessation | Biotech Hunter | Biotech Hunter